title: U.S. Food and Drug Administration clinical trial of the Implantable Contact Lens for moderate to high myopia.
abstract: OBJECTIVE
  To assess the safety and efficacy of the Implantable Contact Lens (ICL) to treat moderate to high myopia.
  
  
  METHODS
  Prospective nonrandomized clinical trial.
  
  
  METHODS
  Five hundred twenty-three eyes of 291 patients with between 3 and 20.0 diopters (D) of myopia participating in the U. S. Food and Drug Administration clinical trial of the ICL for myopia.
  
  
  METHODS
  Implantation of the ICL.
  
  
  METHODS
  Uncorrected visual acuity (UCVA), refraction, best spectacle-corrected visual acuity (BSCVA), adverse events, operative and postoperative complications, lens opacity analysis (Lens Opacity Classification System III), subjective satisfaction, and symptoms.
  
  
  RESULTS
  Twelve months postoperatively, 60.1% of patients had a visual acuity of 20/20 or better, and 92.5% had an uncorrected visual acuity of 20/40 or better. Patients averaged a 10.31-line improvement in UCVA, 61.6% of patients were within 0.5 D, and 84.7% were within 1.0 D of predicted refraction. Only one case (0.2%) lost > 2 lines of BSCVA. Gains of 2 or more lines of BSCVA occurred in 55 cases (11.8%) at 6 months and 41 cases (9.6%) at 1 year after ICL surgery. Early and largely asymptomatic, presumably surgically induced anterior subcapsular (AS) opacities were seen in 11 cases (2.1%); an additional early AS opacity (0.2%) was seen because of inadvertent anterior chamber irrigation of preservative-containing solution at surgery. Two (0.4%) late (> or = 1 year postoperatively) AS opacities were observed. Two (0.4%) ICL removals with cataract extraction and intraocular lens implantation have been performed. Patient satisfaction (very/extremely satisfied) was reported by 92.4% of subjects on the subjective questionnaire; only four patients (1.0%) reported dissatisfaction. Slightly more patients reported an improvement at 1 year over baseline values for the following subjective symptoms: quality of vision, glare, double vision, and night driving difficulties. Only a 3% difference between pre-ICL and post-ICL surgery was reported for haloes.
  
  
  CONCLUSIONS
  The results support the safety, efficacy, and predictability of ICL implantation to treat moderate to high myopia.
authors.affiliation: Center for Clinical Research, Chicago, IL, USA.
authors.forename: Donald R
authors.initials: DR
authors.lastname: Sanders
authors.forename: John A
authors.initials: JA
authors.lastname: Vukich
authors.forename: Kimberley
authors.initials: K
authors.lastname: Doney
authors.forename: Monica
authors.initials: M
authors.lastname: Gaston
mesh_terms: D000328:Adult; D000867:Anterior Chamber / Q000601:surgery*; D001672:Biocompatible Materials; D015331:Cohort Studies; D003263:Contact Lenses, Hydrophilic; D005260:Female; D006801:Humans; D007429:Intraocular Pressure; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000601:surgery*; D017060:Patient Satisfaction; D011183:Postoperative Complications; D011446:Prospective Studies; D019919:Prosthesis Implantation; D012029:Refraction, Ocular; D012449:Safety; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D014792:Visual Acuity
chemical_list: D001672:Biocompatible Materials